We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
After two days of negotiations in Buenos Aries, Argentina, drug manufacturers have agreed to reduce the prices of HIV/AIDS therapies used in treatment programmes in Latin America by as much as 15-55%.
Medicines Australia, a national body representing research-based drugmakers, has called for the government to reform the country's Pharmaceutical Benefits Scheme.
BioVeris Corporation (Nasdaq: BIOV) announced today that on August 9, 2005, it completed a Technology License Agreement with Baxter Healthcare Corporation for exclusive patent rights to a broad portfolio of vaccine candidates.
Axcan Pharma Inc. (AXP.TO: Quote, Profile, Research) (AXCA.O: Quote, Profile, Research), which specializes in gastrointestinal treatments, said on Thursday its quarterly profit fell 67 percent due in part to higher research, selling and administration costs.
Algerian expenditure on imports of pharmaceuticals is expected surpass $1 billion by the end of this year, compared to $967.72 million in 2004, reported the August 9 edition of Al-Khabar daily. Expenditure on these imports during the first half of 2005 hit $520 million.
United Therapeutics Corporation (Nasdaq: UTHR -- News) announced today that the European Union Mutual Recognition Procedure (MRP) has been completed for Remodulin (treprostinil sodium) Injection for the subcutaneous treatment of NYHA Class III Primary Pulmonary Hypertension patients.
German biotech firm Avontec GmbH announced on Thursday that it has raised €14.5 million ($18 million) in a second round of financing that combined an equity deal with a cross-licensing agreement.